These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 6607323)

  • 1. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
    Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
    J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials.
    Ernstoff MS; Fusi S; Kirkwood JM
    J Biol Response Mod; 1983; 2(6):540-7. PubMed ID: 6607324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of natural killing activity by lymphoblastoid interferon in cancer patients.
    Koren HS; Brandt CP; Tso CY; Laszlo J
    J Biol Response Mod; 1983; 2(2):151-65. PubMed ID: 6644332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological effects of recombinant interferon-alpha 2 in cancer patients.
    Hengst JC; Kempf RA; Kan-Mitchell J; Pham AT; Grunberg SM; Kortes VL; Mitchell MS
    J Biol Response Mod; 1983; 2(6):516-27. PubMed ID: 6663321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases.
    Paolozzi F; Zamkoff K; Doyle M; Konrad M; Bradley EC; Rudolph A; Newman N; Gullo J; Scalzo A; Poiesz B
    J Biol Response Mod; 1989 Apr; 8(2):122-39. PubMed ID: 2786553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.
    Rinehart J; Malspeis L; Young D; Neidhart J
    Cancer Res; 1986 Oct; 46(10):5364-7. PubMed ID: 3756886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
    Zinzani PL; Levrero MG; Lauria F; Rondelli D; Zaja F; Russo D; Fanin R; De Rossi G; Mauro FR; Bendandi M; Gozzetti A; Dianzani F; Mandelli F; Tura S
    Haematologica; 1994; 79(1):55-60. PubMed ID: 15378949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Phase II study of recombinant leukocyte A interferon (Ro 22-8181) in hematological malignancies].
    Gan To Kagaku Ryoho; 1985 Apr; 12(4):928-35. PubMed ID: 3885864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I evaluation of a synthetic mutant of beta-interferon.
    Hawkins M; Horning S; Konrad M; Anderson S; Sielaff K; Rosno S; Schiesel J; Davis T; DeMets D; Merigan T
    Cancer Res; 1985 Nov; 45(11 Pt 2):5914-20. PubMed ID: 4053062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant leukocyte A interferon in B-cell chronic lymphocytic leukemia: in vivo effects on autologous antitumor immunity.
    Schulof RS; Lloyd MJ; Stallings JJ; Mai D; Phillips TM; Jones GJ; Schechter GP
    J Biol Response Mod; 1985 Jun; 4(3):310-23. PubMed ID: 3874930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase-1 study of the tolerance for increasing doses of recombinant human alpha 2 interferon in patients with advanced cancer].
    Bretaudeau B; Palangie T; Giralt E; Jouve M; Pouillart P; Falcoff E; Fridman WH; Magdelenat H; Derstepani L; Laurent T
    Bull Cancer; 1984; 71(1):40-9. PubMed ID: 6713113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of rDNA human alpha-2 interferon in multiple myeloma.
    Wagstaff J; Loynds P; Scarffe JH
    Cancer Treat Rep; 1985 May; 69(5):495-8. PubMed ID: 4005872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of Wellferon (human lymphoblastoid alpha-interferon) as cancer therapy: clinical results.
    Sarna G; Figlin R; McCarthy S
    J Biol Response Mod; 1983; 2(2):187-95. PubMed ID: 6644335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parameters of interferon action: I. Immunological effects of whole cell leukocyte interferon (IFN-alpha) in phase I-II trials.
    Ernstoff MS; Fusi S; Kirkwood JM
    J Biol Response Mod; 1983; 2(6):528-39. PubMed ID: 6363630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of natural human interferon beta in metastatic malignancy.
    Bukowski RM; Sergi JS; Sharfman WJ; Budd GT; Murthy S; Barna B; Medendorp SV; Yen-Lieberman B; Gibson V; Bauer L
    Cancer Res; 1991 Feb; 51(3):836-40. PubMed ID: 1988123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.
    Krigel RL; Padavic-Shaller KA; Rudolph AR; Litwin S; Konrad M; Bradley EC; Comis RL
    Cancer Res; 1988 Jul; 48(13):3875-81. PubMed ID: 3132324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
    Kolitz JE; Wong GY; Welte K; Merluzzi VJ; Engert A; Bialas T; Polivka A; Bradley EC; Konrad M; Gnecco C
    J Biol Response Mod; 1988 Oct; 7(5):457-72. PubMed ID: 3263471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase I-II trial.
    Figlin RA; deKernion JB; Maldazys J; Sarna G
    Cancer Treat Rep; 1985 Mar; 69(3):263-7. PubMed ID: 3978656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
    Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
    Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family.
    Masci P; Olencki T; Wood L; Rybicki L; Jacobs B; Williams B; Faber P; Bukowski R; Tong K; Borden EC
    Clin Pharmacol Ther; 2007 Mar; 81(3):354-61. PubMed ID: 17339865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.